DelveInsight’s PDE4 Inhibitor Market Report projects strong growth through 2034, driven by key players such as Arcutis Biotherapeutics, Pfizer, Shionogi, Palisade Bio, UNION Therapeutics, Amgen, and Chiesi Farmaceutici. Major assets including ZORYVE, EUCRISA, OTEZLA, Zatolmilast, and PALI-2108 continue to advance across multiple inflammatory indications. Phosphodiesterase-4 (PDE4)...